| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $100.9M | — | -5.2% |
| SG&A Expense | $24.4M | — | +53.1% |
| Operating Income | -$125.3M | — | -2.4% |
| Net Income | -$120.9M | — | -4.8% |
| EPS (Basic) | -$0.73 | — | +30.5% |
| EPS (Diluted) | -$0.73 | — | +30.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $753.1M | -15.7% | +59.5% |
| Current Assets | $1.02B | -9.4% | +48.1% |
| Total Assets | $1.08B | -9.0% | +49.8% |
| Current Liabilities | $51.2M | +1.2% | +51.3% |
| Long-term Debt | $149.4M | +0.3% | — |
| Total Liabilities | $214.9M | +0.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$144.9M | — | -36.9% |
| Capital Expenditures | $221K | — | -77.5% |
| Investing Cash Flow | -$2.4M | — | -264.1% |
| Financing Cash Flow | $7.1M | — | -95.0% |
| Free Cash Flow | -$145.1M | — | -35.8% |
| +312.5% |
| Stockholders' Equity | $865.1M | -11.0% | +29.3% |